NanoBio® to Present Clinical Data on its Nanoemulsion Adjuvanted Intranasal Flu Vaccine and Novel Anti-Acne Treatment at I

ANN ARBOR, Mich.--(BUSINESS WIRE)-- NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15. The presentation details are as follows:

Poster Presentation G1-197, #206 – “Phase I Study of a Nanoemulsion Adjuvanted Nasal Influenza Vaccine Demonstrates Both Mucosal and Systemic Immune Responses in Humans”

Date: Sunday, Sept. 12 at 11:30 a.m. ET

During the presentation, NanoBio will share clinical data demonstrating that its nanoemulsion adjuvanted intranasal flu vaccine, NB-1008:

  • Elicited both mucosal and systemic immunity following a single intranasal vaccination;
  • Was safe and well tolerated in healthy adults when administered intranasally;
  • Demonstrated proof-of-concept for needle-free vaccines with increased disease protection that could be valuable for high risk populations.

Poster Presentation L1-1751, #436 – “Evaluation of the Safety and Efficacy of a Novel Anti-Acne Nanoemulsion (NB-003) in a Randomized, Open-Label, Parallel-Group, Single Center Study”

Date: Tuesday, Sept. 14 at 11:15 a.m. ET

During the presentation, NanoBio will share clinical data demonstrating that its topical bactericidal oil-in-water emulsion, NB-003:

  • Demonstrated in vivo reduction of P. acnes, comparable to what has been reported separately for topical antibiotics marketed for the treatment of acne;
  • Was safe and well tolerated in adult subjects when administered topically.

About NanoBio

NanoBio Corporation is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.



CONTACT:

NanoBio Corporation
John Coffey, 734-302-9107
Vice President, Business Development
[email protected]
or
Media Contacts:
Schwartz Communications
Stacey Holifield/Benjamin Navon, 781-684-0770
[email protected]

KEYWORDS:   United States  North America  Massachusetts  Michigan

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.